Abstract
Diabetes is a chronic disease with a rapid increase in incidence, which is a general problem around the world. Two main types of diabetes are included. Polygenic diabetes includes type 1 diabetes (T1D) and type 2 diabetes (T2D), and their monogenic forms are juvenile mature diabetes (MODY) and neonatal diabetes (NDM). CRISPR technology is a gene therapy technology with low cost but very high feasibility. At present, researchers have envisioned the use of CRISPR technology in the treatment of T1D, but this technology has a high off-target rate, immune rejection and no abundant clinical trials in the human body to verify this technology, resulting in the fact that this technology is not really used in clinical treatment. In the middle. This article mainly analyzes and summarizes the problems and solutions encountered by CRISPR-cas9 technology from basic theory to idealized models. This article provides new solutions for the treatment of T1D with CRISPR technology and also provides references for this technology. In addition, problems such as immune rejection in the human body have not been solved. Future research can focus on the solution to the problem of the suppression of cellular immune rejection after treatment and the impact of re-mutation.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call